A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab
Status:
Recruiting
Trial end date:
2021-11-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1b/2a, open-label, multi-center, non-randomized, dose-escalation study of
PT-112 in combination with the anti-PD-L1 antibody, avelumab, in selected advanced solid
tumors. The study is to be conducted in two parts: the Dose Escalation Phase of PT-112 within
the combination and the Dose Confirmation Phase in patients with non-small cell lung cancer
who will be treated at the RP2D.